Domain Therapeutics and Chime Biologics announce manufacturing agreement to advance novel anti-CCR8 antibody for cancer immunotherapy

Chime Biologics France Canada Massachusetts China California Washington

The agreement combines Domain Therapeutics' candidate DT-7012 with Chime Biologics' internationally-recognized manufacturing expertise In June 2023, Domain nominated DT-7012, a Treg depleting anti-CCR8 monoclonal antibody (mAb) with best-in-class potential, which enters Phase I studies in 2025The CCR8 GPCR target is a highly strategic approach in immuno-oncology to increase clinical success rates in non-responding patients View original content:https://www.prnewswire.co.uk/news-releases/domain-therapeutics-and-chime-biologics-announce-manufacturing-agreement-to-advance-novel-anti-ccr8-antibody-for-cancer-immunotherapy-302085515.html